Ophthalmology   

Patient with a history of presumed benign ethnic neutropenia: PMN 1.5 prior to azathioprine and 1.2 after starting. The patient has an intolerance to ...

This question is part of a collaboration with RheumMadness and is specifically in reference to: Cost Effectiveness of HCQ Screening.

The patient has no extraocular features of a spondyloarthropathy and is on methotrexate. No active eye disease for past 1 year.

No active joint disease, patient on Hydroxychloroquine and Cimzia. Normal ESR/CRP.

Patient previously trialed two anti-TNFi and Tocilizumab. Avoiding Rituximab due to positive JC virus testing. 

Can nodular scleritis be a presenting manifestation of GCA?

Is the diagnosis of Sjogren's mostly clinical in a patient with a consistent history and physical with positive serologies?

And have you ever seen it occur in isolation without any other manifestations of SLE? 

Per 2021 GCA Vasculitis Guidelines: low evidence, but conditional recommendation for CTA neck, chest, abd/pelvis. Is anybody following this or do you ...

If so, when do you recommend timing for the cataract surgery? 

Patient is asymptomatic. Labs showed +P-ANCA 1:160. Negative MPO and PR3.

Female patient in her 20's with RA/SLE has been on steroids and methotrexate, currently on HCQ and Orencia. Failing Orencia with active disease. Want ...

Other manifestations improved (renal function has stabilized, fatigue, arthritis, and LCV have resolved). Ophthalmologist has controlled the uveitis u...

Patient with history of toxoplasma chorioretinitis, currently on oral and topical prednisone. 

Patient has failed methotrexate and adalimumab. 

Patient failed topical ocular therapies, methotrexate, azathioprine.

Is the approach different from uveitis immunosuppression?

What immunosuppression and dosing do you typically use?

Are there specific features that suggest drug-induced uveitis versus de novo uveitis?

Thoughts on sarilumab vs methotrexate, or just treat with steroids alone

Are IL-17 or IL-23 inhibitors helpful?

Patient was previously well controlled on methotrexate, which was discontinued during cancer treatment.